ArticleCase reports in emergency medicine2017
Physician Beware: Severe Cyanide Toxicity from Amygdalin Tablets Ingestion.
Article in Case reports in emergency medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 40 citations in OpenAlex.
- Assessing internal disaster preparedness at Security Forces Hospital, Riyadh.Journal of family medicine and primary care · 2025Article
- Genotoxicity and acute toxicity of Hyunburikyung-tang: assessing the safety of prescribing traditional Korean medicine for dysmenorrhea.BMC complementary medicine and therapies · 2025Article
- Nutritional Characterization of Fruits from Three African Plant Species:Plants (Basel, Switzerland) · 2025Article
- Recent Trends in Nanoparticulate Delivery System for Amygdalin as Potential Therapeutic Herbal Bioactive Agent for Cancer Treatment.Current drug delivery · 2025Review
- Cyanide and Cyanogenic Compounds-Toxicity, Molecular Targets, and Therapeutic Agents.Biomolecules · 2024Review
- Amygdalin as a Promising Anticancer Agent: Molecular Mechanisms and Future Perspectives for the Development of New Nanoformulations for Its Delivery.International journal of molecular sciences · 2023Review
- Establishment of a Sonotrode Ultrasound-Assisted Extraction of Phenolic Compounds from Apple Pomace.Foods (Basel, Switzerland) · 2022Article
- In Vitro and In Vivo Evaluation of the Effectiveness and Safety of Amygdalin as a Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Effect on Osteoclast Differentiation and ER Stress Downregulation by Amygdalin and RANKL Binding Interaction.Biomolecules · 2022Article
- Inflammation, It's Regulation and Antiphlogistic Effect of the Cyanogenic Glycoside Amygdalin.Molecules (Basel, Switzerland) · 2021Review
- The Multiple Actions of Amygdalin on Cellular Processes with an Emphasis on Female Reproduction.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Onco-immunity and therapeutic application of amygdalin: A review.Journal of oral biology and craniofacial researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the risk of cyanide toxicity and lack of efficacy, amygdalin is still used as alternative cancer treatment. Due to the highly lethal nature of cyanide toxicity, many patients die before getting medical care. Herein, we describe the case of a 73-year-old female with metastatic pancreatic cancer who developed cyanide toxicity from taking amygdalin. Detailed history and physical examination prompted rapid clinical recognition and treatment with hydroxocobalamin, leading to resolution of her cyanide toxicity. Rapid clinical diagnosis and treatment of cyanide toxicity can rapidly improve patients' clinical outcome and survival. Inquiries for any forms of ingestion should be attempted in patients with clinical signs and symptoms suggestive of poisoning.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.